A new strategy for melanoma treatment: an investigation of the clinical value of the combination of immune checkpoint inhibitors and oncolytic viruses.

ABSTRACT: Melanoma is a highly malignant tumor. In the past, treatment options like chemotherapy were of limited benefit, and its prognosis, particularly in the advanced stage, was poor. The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the therapeutic landscape for melanoma and significantly improved patient survival. However, the efficacy of ICIs monotherapy remains limited, with only a small proportion of cancer patients benefiting. It has been proposed that oncolytic viruses (OVs) can significantly increase the density of CD8 + T-cells in tumors by modulating the tumor microenvironment from "cold" to "hot", and this change can synergistically activate anti-tumor immunity in conjunction with ICIs, thus improving the response rate of ICIs therapy. This change can synergize

SUBMITTER: Sui B 

PROVIDER: S-EPMC12825276 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature